265 related articles for article (PubMed ID: 21880218)
1. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
Cassano N; Mastrandrea V; Principi M; Loconsole F; De Tullio N; Di Leo A; Vena GA
J Biol Regul Homeost Agents; 2011; 25(2):285-9. PubMed ID: 21880218
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
5. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
[TBL] [Abstract][Full Text] [Related]
6. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
Caporali R; Bobbio-Pallavicini F; Atzeni F; Sakellariou G; Caprioli M; Montecucco C; Sarzi-Puttini P
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):749-54. PubMed ID: 20535784
[TBL] [Abstract][Full Text] [Related]
7. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis.
Navarro R; Concha-Garzón MJ; Castaño C; Casal C; Guiu A; Daudén E
Int J Dermatol; 2014 Jul; 53(7):909-11. PubMed ID: 24673290
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
11. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
15. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation and alemtuzumab therapy.
Iannitto E; Minardi V; Calvaruso G; Mulè A; Ammatuna E; Di Trapani R; Ferraro D; Abbadessa V; Craxí A; Di Stefano R
Eur J Haematol; 2005 Mar; 74(3):254-8. PubMed ID: 15693796
[TBL] [Abstract][Full Text] [Related]
17. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.
Gupta S; Singh S
BMC Infect Dis; 2010 Mar; 10():53. PubMed ID: 20205948
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
19. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.
Viganò M; Degasperi E; Aghemo A; Lampertico P; Colombo M
Expert Opin Biol Ther; 2012 Feb; 12(2):193-207. PubMed ID: 22188392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
